CINECA IRIS Institutional Research Information System

CHIRICOZZI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.359
AS - Asia 2.960
EU - Europa 1.968
SA - Sud America 408
AF - Africa 207
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 5
Totale 12.919
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.171
SG - Singapore 907
CN - Cina 896
HK - Hong Kong 610
IT - Italia 433
BR - Brasile 351
GB - Regno Unito 336
BG - Bulgaria 300
SE - Svezia 248
VN - Vietnam 220
CI - Costa d'Avorio 146
RU - Federazione Russa 140
DE - Germania 138
CA - Canada 137
FI - Finlandia 100
TR - Turchia 80
AT - Austria 58
JP - Giappone 58
IN - India 55
FR - Francia 43
MX - Messico 39
LT - Lituania 31
IE - Irlanda 27
NL - Olanda 25
AR - Argentina 18
ES - Italia 18
SN - Senegal 18
BD - Bangladesh 17
IQ - Iraq 16
ID - Indonesia 15
PK - Pakistan 13
PL - Polonia 12
SA - Arabia Saudita 12
CH - Svizzera 11
AU - Australia 10
CO - Colombia 10
EC - Ecuador 10
EG - Egitto 10
PH - Filippine 9
BJ - Benin 8
HU - Ungheria 8
MA - Marocco 8
RO - Romania 8
UA - Ucraina 7
UZ - Uzbekistan 7
KR - Corea 6
ZA - Sudafrica 6
CL - Cile 5
MY - Malesia 5
BE - Belgio 4
BO - Bolivia 4
GR - Grecia 4
IL - Israele 4
JO - Giordania 4
NP - Nepal 4
VE - Venezuela 4
AZ - Azerbaigian 3
BB - Barbados 3
EU - Europa 3
GE - Georgia 3
KG - Kirghizistan 3
OM - Oman 3
PE - Perù 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
BY - Bielorussia 2
DZ - Algeria 2
ET - Etiopia 2
HN - Honduras 2
IR - Iran 2
JM - Giamaica 2
KZ - Kazakistan 2
LB - Libano 2
MT - Malta 2
NZ - Nuova Zelanda 2
PA - Panama 2
PT - Portogallo 2
PY - Paraguay 2
SK - Slovacchia (Repubblica Slovacca) 2
AO - Angola 1
CR - Costa Rica 1
CW - ???statistics.table.value.countryCode.CW??? 1
CZ - Repubblica Ceca 1
HR - Croazia 1
KE - Kenya 1
KH - Cambogia 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
NE - Niger 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
PS - Palestinian Territory 1
RS - Serbia 1
TZ - Tanzania 1
UG - Uganda 1
UY - Uruguay 1
VG - Isole Vergini Britanniche 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 12.918
Salva come PNG Salva come JPEG
Città #
Ashburn 879
Fairfield 838
Woodbridge 678
Hong Kong 608
Santa Clara 527
Singapore 480
Houston 479
Ann Arbor 432
Seattle 349
Chandler 307
Sofia 299
Cambridge 293
Wilmington 273
Beijing 270
Shanghai 248
Lancaster 227
New York 214
Dallas 163
Abidjan 145
Princeton 129
Boardman 122
Lawrence 111
Medford 107
Ottawa 101
Serra 99
Des Moines 90
Los Angeles 89
Nanjing 61
Dong Ket 59
Istanbul 57
London 51
Redondo Beach 47
San Diego 43
Guangzhou 41
Florence 39
Buffalo 37
Vienna 36
Redwood City 34
Washington 33
Dearborn 31
Phoenix 28
Munich 26
Frankfurt am Main 24
Milan 23
Siauliai 22
Tokyo 21
Düsseldorf 20
Rome 20
São Paulo 20
Chicago 19
Nanchang 19
Rio de Janeiro 19
Dakar 18
Turku 17
Changsha 16
Kunming 15
Ho Chi Minh City 14
Belo Horizonte 13
Jiaxing 13
Paris 12
Hebei 11
Shenyang 11
Montreal 10
Norwalk 10
Toronto 10
Bremen 9
Council Bluffs 9
Detroit 9
Hangzhou 9
Hanoi 9
Nuremberg 9
Atlanta 8
Cotonou 8
Bologna 7
Brooklyn 7
Fuzhou 7
Helsinki 7
Porto Alegre 7
San Francisco 7
San Jose 7
Tashkent 7
Baghdad 6
Cairo 6
Campinas 6
Dhaka 6
Guayaquil 6
Hefei 6
Jinan 6
Kent 6
Oranmore 6
Pisa 6
Amsterdam 5
Berlin 5
Boston 5
Brasília 5
Budapest 5
Chennai 5
Esslingen am Neckar 5
Guadalajara 5
Indiana 5
Totale 9.788
Salva come PNG Salva come JPEG
Nome #
Trattamento topico delle dermatiti da contatto: validazione scientifica di una crema lenitiva a base di biotina, L-carnitina, pantenolo, α-bisabololo e tocoferolo. [Topical treatment of contact dermatitis with natural active principles] 236
Assessment of disease severity and treatment effectiveness in hidradenitis suppurativa 225
Sensors and Biosensors for C-Reactive Protein, Temperature and pH, and Their Applications for Monitoring Wound Healing: A Review 192
AISI: A New Disease Severity Assessment Tool for Hidradenitis Suppurativa 179
Potential correlation of wound bed score and biomarkers in chronic lower leg wounds: an exploratory study 179
Nanomedicine in dermatology: Benefits and emerging applications 164
Complete Resolution of Erythrodermic Psoriasis in an HIV and HCV Patient Unresponsive to Antipsoriatic Treatments after Highly Active Antiretroviral Therapy (Ritonavir, Atazanavir, Emtricitabine, Tenofovir). 154
Optimizing acitretin use in patients with plaque psoriasis 153
Alexithymia affects patients with hidradenitis suppurativa 151
Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. 148
The Quality of Life impairment in Hidradenitis Suppurativa 147
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis 147
Acne fulminans associated with lymecycline intake: A case report 146
Deep pulse fractional CO2 laser combined with a radiofrequency system: results of a case series 145
Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry 144
Risankizumab for the treatment of moderate to severe psoriasis 143
A new therapeutic for the treatment of moderate to severe plaque psoriasis: apremilast 141
TSLP-activated dendritic cells induce human T follicular helper cell differentiation through OX40-ligand 140
UVA-1 Laser in the Treatment of Palmoplantar Pustular Psoriasis 138
Gynecomastia following isotretinoin treatment: a rare endocrine side effect 138
Long-Term Outcome of Adalimumab in a Young Girl with Hidradenitis Suppurativa 138
Apremilast for the treatment of psoriasis 137
Spotlight on dupilumab in the treatment of atopic dermatitis: Design, development, and potential place in therapy 137
Improvement of severe facial seborrheic dermatitis following low-dose isotretinoin therapy 137
Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris 136
Biomarkers for psoriasis skin lesions 136
Atopic dermatitis keratinocytes exhibit normal T(H)17 cytokine responses 133
IL-6 as a druggable target in psoriasis: Focus on pustular variants 133
Isotretinoin-triggered acne fulminans: a rare, disabling occurrence 133
Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis. 131
A revolutionary therapeutic approach for psoriasis: bispecific biological agents. 131
Hidradenitis Suppurativa Associated with Down Syndrome Is Characterized by Early Age at Diagnosis 130
A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents 129
Relevance of in vitro 3-D skin models in dissecting cytokine contribution to psoriasis pathogenesis 128
Cutaneous human papillomaviruses as recurrence factor in actinic keratoses 127
Pathogenic role of IL-17 in psoriasis and psoriatic arthritis 126
New insights in the pathogenesis of cutaneous autoimmune disorders. 126
Treatment of psoriasis with topical agents: Recommendations from a Tuscany Consensus 126
HIDRAdisk: an innovative visual tool to assess the burden of hidradenitis suppurativa 124
Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. 123
Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis 123
Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments 122
Scanning the immunopathogenesis of psoriasis 122
Gene Expression Profiling Associated with the Progression of Classic Kaposi’s Sarcoma. 122
Tofacitinib for the treatment of moderate-to-severe psoriasis 122
A giant annular rash in a tuscanian woodman: the many faces of erythema chronicum migrans 122
Lasers and Energy Devices for the Skin: Conventional and Unconventional Use 122
Current therapeutic paradigm in pediatric atopic dermatitis: Practical guidance from a national expert panel 121
Effective topical agents and emerging perspectives in the treatment of psoriasis. 120
Profile of certolizumab and its potential in the treatment of psoriatic arthritis. 120
Usefulness of QuantiFERON®-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers. 119
Integrative responses to IL-17 and TNF-a in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. 118
Efficacy and safety of Infliximab in psoriatic patients over the age of 65 117
Quality of life of psoriatic patients evaluated by a new psychometric assessment tool: PsoDisk. 117
Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. 116
The management of moderate-to-severe chronic plaque psoriasis 116
The new era for the treatment of psoriasis and psoriatic arthritis: Perspectives and validated strategies. 115
Trattamento topico della xerosi cutanea severa: risultati di uno studio osservazionale. [Topical treatment of severe xerosis: Results of an observational study] 114
Thymic stromal lymphopoietin links keratinocytes and dendritic cell-derived IL-23 in patients with psoriasis 114
Apheresis in the treatment of recalcitrant atopic dermatitis: Case series and review of the literature 114
Potential role of serum amyloid A in hidradenitis suppurativa 114
New topical treatments for psoriasis 113
Small molecules and antibodies for the treatment of psoriasis: A patent review (2010–2015) 113
Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target? 113
Granuloma annulare: A case treated with infliximab successfully 112
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis 112
Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. 111
Biomolecular index of therapeutic efficacy in psoriasis treated by anti-TNF alpha agents 110
Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy 110
No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents 109
PsAPASH: A new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition 109
IL-17 targeted therapies for psoriasis. 108
Golimumab in Patients Affected by Moderate to Severe Psoriatic Arthritis: An Open-Label Study in Thirty-Two Patients Previously Treated with Other Biologics 108
Emerging applications of nanomedicine in dermatology 108
Ustekinumab for treatment of plaque psoriasis in patient with Down Syndrome. 108
An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis 107
Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: Results of a single-centre, retrospective study 107
Characterization of comorbid conditions burdening hidradenitis suppurativa: a multicentric observational study 107
IL-17 Induces an Expanded Range of Downstream Genes in Reconstituted Human Epidermis Model. 106
Adipose tissue response to IL-17 combined with TNF-alpha exposure 106
Elderly psoriatic patients under biological therapies: an Italian experience 106
Increased levels of IL-17 in tear fluid of moderate-to-severe psoriatic patients is reduced by adalimumab therapy 106
Unconventional Use of Intense Pulsed Light 105
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris. 104
Modulation of inflammatory gene transcripts in psoriasis vulgaris: Differences between ustekinumab and etanercept 104
Immunologic biomarkers for clinical and therapeutic management of psoriasis 102
Urticaria associated with hyper-IgE in a patient with psoriasis undergoing treatment with efalizumab. 100
Genetic Markers for Cardiovascular Disease in Psoriasis: The Missing Piece. 100
Testing biologics and intracellular signaling inhibitors on pediatric atopic dermatitis: a stairway to modern therapeutic approaches 100
Dusky Red Swelling of the Penis in Association with Fever and Diarrhoea: A Quiz. 99
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases. 97
Psoriasis Phenotype in Inflammatory Bowel Disease: A Case-Control Prospective Study 96
European consensus statement on phenotypes of pustular psoriasis 96
The Hidradenitis Suppurativa (HS) “Multidisciplinary Unit”: a rationale and practical proposal for an organised clinical approach 95
Hidradenitis suppurativa: guidelines of the Italian Society of Dermatology and Venereology (SIDeMaST) for the use of anti-TNF-α agents 93
Un nuovo approccio fototerapico alle dermatosi croniche 92
HS-TIME: A Modified TIME Concept in Hidradenitis Suppurativa Topical Management 92
Use of Vitamins and their Derivates in the Treatment of Cutaneous Disorders. 91
Dermal CARD14 expression in psoriasis 91
Psoriasis 90
Totale 12.357
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.001
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.001
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021551 0 0 0 0 0 54 37 51 84 77 43 205
2021/20221.112 23 42 46 65 230 159 21 81 42 16 45 342
2022/20231.155 159 166 80 62 110 117 16 83 258 5 82 17
2023/2024768 36 39 90 30 110 243 20 42 6 23 14 115
2024/20252.905 6 116 28 128 366 349 233 147 269 441 310 512
2025/20261.616 209 315 205 158 379 350 0 0 0 0 0 0
Totale 13.304